210 722 1732

Obesity-Modifying Medications

Modern medications—liraglutide, semaglutide, tirzepatide—mimic gut hormones that regulate appetite and glucose metabolism. They have revolutionized non-surgical obesity treatment.

Expected Weight Loss

  • Liraglutide: 5–10% TWL in 6–12 months.
  • Semaglutide: 15–20% TWL in 12–16 months.
  • Tirzepatide: Up to 20–25% TWL in 12–16 months.
Reference: Pantelis AG & Lapatsanis DP Metab Target Organ Damage 2023;3:17.

Administration

Subcutaneous injections — daily (liraglutide) or weekly (semaglutide, tirzepatide).

Advantages

  • Effective, sustained weight reduction while on therapy.
  • Improved metabolic health: Better glycemic control, blood pressure, and lipid profile.
  • Convenient dosing.
  • Enhanced outcomes when combined with balanced nutrition and regular exercise.
  • Possible alternative or bridge to surgery in selected patients.

Important Notes

  • Side effects: Mainly mild gastrointestinal symptoms (nausea, vomiting, diarrhea) that usually improve over time.
  • Maintenance: Weight tends to regain if treatment stops; long-term therapy or structured transition is needed.
  • Individualization: Choice of drug depends on medical history and weight-loss goals, guided by specialized clinicians.

Key Takeaways for All Bariatric Patients

  • Expected average loss: 25–35% TWL for surgical procedures (varies by technique and follow-up).
  • Major complication rate: ~1–2% in experienced centers.
  • Mortality: 0.1–0.3%.
  • Lifelong follow-up and supplementation are mandatory to maintain health and results.